Almonertinib and alflutinib show novel inhibition on rare EGFR S768I mutant cells-Reference-Cited by-同舟云学术

Almonertinib and alflutinib show novel inhibition on rare EGFR S768I mutant cells

Published:2024-05-30 Issue: Volume: Page:
ISSN:1699-3055
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Wei Xiangkai,Zhang Guoliang,Liu Qian,Niu Zhiyuan,Chu Chunhong,Liu Chenxue,Wang Ke,Li Lanxin,Wang Rui,Cui Wenrui,Xu Huixia,Liu Chenyang,Wang Ying,An Lei^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12094-024-03494-5.pdf

Reference23 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

2. Heng J, Tang Q, Chen X, Bao J, Deng J, Chen Y, et al. Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. Eur J Pharm Sci. 2021;162: 105815.

3. Abdelmaksoud-Dammak R, Ammous-Boukhris N, Saadallah-Kallel A, Charfi S, Khemiri S, Khemakhem R, et al. Predominance of the rare EGFR mutation p.L861Q in Tunisian patients with non-small cell lung carcinoma. Genes (Basel). 2022;13(8):1499.

4. Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: from molecular mechanisms to clinical research. Pharmacol Res. 2021;167: 105583.

5. Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020;61:167–79.